Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)-Reference-Cited by-同舟云学术

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)

Published:2017-07-04 Issue:4 Volume:18 Page:164-173
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Kulkarni Rima¹,Hodder Sally L.²^ORCID,Cao Huyen³,Chang Silvia¹,Miller Michael D.¹,White Kirsten L.¹

Affiliation:

1. Clinical Virology, Gilead Sciences, Inc., Foster City, CA, USA

2. Health Sciences Center, West Virginia Clinical and Translational Science Institute Morgantown, WV, USA

3. Clinical Research, Gilead Sciences, Inc., Foster City, CA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

https://www.tandfonline.com/doi/pdf/10.1080/15284336.2017.1370059

Reference20 articles.

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global aids update 2016. Available at: https://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016. May 31, 2016.

2. Women in Clinical Trials: an FDA Perspective

3. Inclusion of Women in Clinical Trials -- Policies for Population Subgroups

4. Meta-Analysis of Gender Differences in Efficacy Outcomes for HIV-Positive Subjects in Randomized Controlled Clinical Trials of Antiretroviral Therapy (2000–2008)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sexual satisfaction and its associations with patient-reported outcomes in a cohort of women living with human immunodeficiency virus in Sweden;International Journal of STD & AIDS;2022-05-27

2. Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment;Clinical Infectious Diseases;2020-10-23

3. Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir;Open Forum Infectious Diseases;2018-09-08

4. HIV;The Lancet;2018-08